Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

2023-05-25
PRNewswire
临床1期引进/卖出孤儿药临床2期
The prevalence of idiopathic pulmonary fibrosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of idiopathic pulmonary fibrosis and the growing research and development activities to develop novel therapies to treat idiopathic pulmonary fibrosis to drive the market. The companies developing the potential therapies in the last stage of development include
FibroGen, Boehringer Ingelheim, and several others.
LAS VEGAS, May 25, 2023 /PRNewswire/ -- DelveInsight's
'
Idiopathic Pulmonary Fibrosis Pipeline Insight – 2023
' report provides comprehensive global coverage of pipeline idiopathic pulmonary fibrosis therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the idiopathic pulmonary fibrosis pipeline domain.
Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report
DelveInsight's idiopathic pulmonary fibrosis pipeline report depicts a robust space with
80+ active players working to develop
100+ pipeline therapies for idiopathic pulmonary fibrosis treatment.
Key idiopathic pulmonary fibrosis companies such as
FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others are evaluating new idiopathic pulmonary fibrosis drugs to improve the treatment landscape.
Promising idiopathic pulmonary fibrosis pipeline therapies in various stages of development include
Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others.
In
May 2023, Kinarus Therapeutics announced the signing of a strategic convertible loan agreement for a
CHF 1.5 million investment by
ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China ("CDIM"). Further, this agreement forms the basis for discussions on the introduction, development and commercialization of
KIN001 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, introduced CDIM to Kinarus.
In April 2023, AGC Biologics announced it signed a service agreement with
The Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.
In February 2023, Insilico Medicine announced that the US Food and Drug Administration (FDA) had granted
Orphan Drug Designation to
In February 2023, Arrowhead Pharmaceuticals Inc. announced that it had dosed the first subjects in a Phase I/IIa clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
In February 2023, South Korea's Daewoong Pharmaceutical secured an exclusive licensing agreement with
CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in the Greater China region, including mainland China, Hong Kong, Taiwan, and Macau. Under this agreement, CSP will in-license
Bersiporocin for Idiopathic Pulmonary Fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to
$336 million, including up to
$76 million in upfront and development milestone payments and double-digit royalties on Net Sales.
In January 2023, Insilico Medicine announced the positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase 1 clinical trial of
INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for idiopathic pulmonary fibrosis (IPF).
In January 2023, Pliant Therapeutics announced 12-week
interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of
bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF).
In December 2022, Vallon Pharmaceuticals announced that they entered into a
definitive agreement (the "Merger Agreement") pursuant to which
GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction (the "Merger"). The combined company will focus on advancing GRI Bio's innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Following the closing of the Merger, the combined company is expected to operate under the name
Request a sample and discover the recent advances in idiopathic pulmonary fibrosis drug treatment @
The idiopathic pulmonary fibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage idiopathic pulmonary fibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the idiopathic pulmonary fibrosis clinical trial landscape.
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that primarily affects middle-aged and older adults. It affects lung tissue by thickening, stiffening, or persistent and progressive scarring that worsens irreversibly over time. Scarring affects the air sacs of IPF patients, decreasing the amount of oxygen that enters the circulation. With less oxygen in the blood, ordinary tasks such as walking can cause dyspnea. This set of lung illnesses is also known as 'Diffuse Parenchymal Lung Diseases,' and it is distinguished by a broader umbrella of 'Interstitial Lung Diseases (IDLs)'. The cause of IPF is uncertain; experts believe the condition is caused by a mix of hereditary and environmental factors. There is a significant chance that genetic variations enhance a person's risk of acquiring IPF and then being exposed to environmental variables that aggravate the condition. However, much remains unknown about this new field of study.
Find out more about drugs for idiopathic pulmonary fibrosis @
A snapshot of the Idiopathic Pulmonary Fibrosis Pipeline Drugs mentioned in the report:
Learn more about the emerging idiopathic pulmonary fibrosis pipeline therapies @
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
The idiopathic pulmonary fibrosis pipeline report proffers an integral view of idiopathic pulmonary fibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
Coverage: Global
Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
Key Idiopathic Pulmonary Fibrosis Pipeline Therapies: Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others.
Dive deep into rich insights for new drugs for idiopathic pulmonary fibrosis treatment; visit @
Table of Contents
For further information on the idiopathic pulmonary fibrosis pipeline therapeutics, reach out @
Related Reports
Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key idiopathic pulmonary fibrosis companies, including
Idiopathic Pulmonary Fibrosis Epidemiology Forecast
Idiopathic Pulmonary Fibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and idiopathic pulmonary fibrosis epidemiology trends.
Pulmonary Fibrosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary fibrosis companies, including
Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary fibrosis companies, including
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。